Similar articles

• Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.

  Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Koiwa F, et al. Nephrology (Carlton). 2017 Apr;22(4):293-300. doi: 10.1111/nep.12891. Nephrology (Carlton). 2017. PMID: 27496336 Free PMC article. Clinical Trial.
• A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.

  Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group. Floege J, et al. Kidney Int. 2014 Sep;86(3):638-47. doi: 10.1038/ki.2014.58. Epub 2014 Mar 19. Kidney Int. 2014. PMID: 24646861 Free PMC article. Clinical Trial.
• Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.

  Koiwa F, Terao A. Koiwa F, et al. Clin Exp Nephrol. 2017 Jun;21(3):513-522. doi: 10.1007/s10157-016-1299-z. Epub 2016 Jul 7. Clin Exp Nephrol. 2017. PMID: 27389681 Free PMC article. Clinical Trial.
• A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.

  Bousher A, Al-Makki A, Sutton J, Shepler B. Bousher A, et al. Clin Ther. 2014 Dec 1;36(12):2082-2093. doi: 10.1016/j.clinthera.2014.09.021. Epub 2014 Oct 29. Clin Ther. 2014. PMID: 25450474 Review.
• Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.

  Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer JP. Sinsakul M, et al. Expert Rev Clin Pharmacol. 2014 Nov;7(6):705-10. doi: 10.1586/17512433.2014.960848. Epub 2014 Sep 22. Expert Rev Clin Pharmacol. 2014. PMID: 25242077 Review.